Glasgow scientists develop first bone marrow model to support human stem cells
LT-HSCs replenish blood cells after treatment for blood cancers, such as leukaemia
Read More
Tag: blood cancer
KCL leads first guidelines on immune monitoring for hard-to-treat blood cancer
Myelodysplastic syndromes are a group of blood cancers that currently affect more than 7,000 people in the UK
Read More
Kite and Refuge Biotechnologies to work together to research blood cancer
The licence agreement bolsters Kite’s expertise in synthetic biology for oncology
Read More
Cancer Research UK partners with Aleta Biotherapeutics on blood cancer therapy
Partnership will advance the early clinical development of CAR-T cell engager candidate ALETA-001
Read More
Researchers identify new genetic target for acute myeloid leukaemia
Targeting a specific mutation in the CUX1 gene may offer a ‘new therapy avenue’ for AML patients
Read More
Roche reveals new bispecific antibody data in blood cancers
‘Encouraging’ data for investigational candidates across a range of blood cancers
Read More
AbbVie’s Venclyxto shows promise as AML treatment
The drug is already on the market to treat chronic lymphocytic leukaemia (CLL)
Read More
J&J launches ‘Make Blood Cancer Visible’ campaign
The company has released a short documentary and five mini-films, outlining the symptoms that led patients to their diagnosis.
Read More
NICE OKs three new therapies for blood cancer
Cost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales.
Read More
Blood cancer care needs improving, finds MP inquiry
The Government’s 2015 Cancer Strategy is failing to support blood cancer patients in the UK and care must improve, an MP inquiry has found.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
